Skip to main content

Unum Group

For the period ended Dec 31, 2023. Filed Feb 20, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 20, 2024

UNM$76.75+3.8%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Colonial Life Segment

The Colonial Life segment includes insurance for accident, sickness, and disability products, which includes dental and vision products, life products, and cancer and critical illness products. These products are marketed to employees, on both a group and an individual basis, at the workplace through an independent contractor agent sales force and brokers.

Shown below are financial results and key performance indicators for the Colonial Life segment.

(in millions of dollars, except ratios)
Year Ended December 31
2023 · % Change · 2022 · % Change · 2021
Adjusted Operating Revenue
Premium Income
Accident, Sickness, and Disability$946.1(0.3)%$948.9(0.5)%$953.3
Life426.56.3401.14.3384.7
Cancer and Critical Illness353.50.4352.0(0.1)352.2
Total Premium Income1,726.11.41,702.00.71,690.2
Net Investment Income153.50.5152.7(11.2)172.0
Other Income1.29.11.110.01.0
Total1,880.81.31,855.8(0.4)1,863.2
Benefits and Expenses
Policy Benefits877.1(5.3)926.6(4.5)969.8
Policy Benefits - Remeasurement Gain(79.0)(21.4)(100.5)73.0(58.1)
Commissions359.45.7340.06.2320.1
Deferral of Acquisition Costs(302.9)11.4(271.8)7.6(252.6)
Amortization of Deferred Acquisition Costs205.419.4172.08.0159.2
Other Expenses340.05.8321.48.2297.0
Total1,400.00.91,387.7(3.3)1,435.4
Income Before Income Tax and Net Investment Gains and Losses480.82.7468.19.4427.8
Reserve Assumption Updates(80.7)46.2(55.2)134.9(23.5)
Adjusted Operating Income$400.1(3.1)$412.92.1$404.3
Operating Ratios (% of Premium Income):
Benefit Ratio150.9%51.8%55.3%
Other Expense Ratio19.7%18.9%17.6%
Income Ratio27.9%27.5%25.3%
Adjusted Operating Income Ratio23.2%24.3%23.9%
Persistency:
Accident, Sickness, and Disability73.6%73.3%75.4%
Life85.1%84.5%85.5%
Cancer and Critical Illness82.4%82.3%82.4%
1Excludes the reserve assumption updates that occurred during the third quarters of 2023, 2022, and 2021.

Premium income was favorable compared to 2022 due to higher prior period sales, particularly in the life product line, and favorable persistency. Net investment income was generally consistent in 2023 compared to 2022 with an increase in the level of invested assets and an increase in the yield on invested assets, mostly offset by lower miscellaneous investment income.

The benefit ratio, excluding the impacts of the reserve assumption updates, was favorable relative to 2022 due primarily to lower claim costs in the cancer and critical illness product line and favorable mortality experience as a result of lessening impacts of COVID-19 on our insured population in the life product line, partially offset by an increase in reserves due to model refinements in the life product line.

Commissions and the deferral of acquisition costs were higher compared to 2022 due to higher prior period sales. The amortization of deferred acquisition costs was higher compared to 2022 primarily due to growth in the level of the deferred asset and the impact of the policyholder lapses. The other expense ratio was higher relative to 2022 due primarily to an increase in employee-related costs and an increase in operational investments in our business.

Premium income was favorable compared to 2021 due to higher prior period sales, partially offset by lower overall persistency. Net investment income was lower in 2022 compared to 2021 due to lower miscellaneous investment income and a decline in the yield on invested assets, partially offset by an increase in the level of invested assets.

The benefit ratio, excluding the impacts of the reserve assumption updates, was favorable relative to 2021 across all product lines, including the life product line as a result of the lessening impacts of COVID-19 on our insured population.

Commissions and the deferral of acquisition costs were higher compared to 2021 due to higher prior period sales. The amortization of deferred acquisition costs was higher compared to 2021 due to higher policyholder lapses primarily in the accident, sickness, and disability product line. The other expense ratio was higher relative to 2021 due primarily to an increase in the operational investments in our business, an increase in employee-related costs, and a decrease in the allowance for expected credit losses during 2021 that did not recur in 2022.

Sales

(in millions of dollars)
Year Ended December 31
2023% Change2022% Change2021
Sales by Product
Accident, Sickness, and Disability$329.56.1%$310.64.3%$297.9
Life132.18.7121.59.5111.0
Cancer and Critical Illness78.02.676.07.270.9
Total Sales$539.66.2$508.15.9$479.8
Sales by Market Sector
Commercial
Core Market (< 1,000 employees)$347.44.5%$332.46.1%$313.2
Large Case Market62.37.258.1(15.2)68.5
Subtotal409.74.9390.52.3381.7
Public Sector129.910.5117.619.998.1
Total Sales$539.66.2$508.15.9$479.8

During 2023, we have seen an increase in sales for each of our product lines relative to 2022. Commercial market sales increased compared to 2022 driven by higher sales to new and existing customers in the core market, which we define as accounts with fewer than 1,000 employees, and higher sales to new and existing customers in the large case market. Public sector market sales increased compared to 2022 due to higher sales to existing customers.

During 2022, we saw an increase in sales for each of our product lines relative to 2021. Commercial market sales increased compared to 2021 driven by higher sales to existing customers in the core market partially offset by lower sales to new and existing customers in the large case market. Public sector market sales increased compared to 2021 due to higher sales to both new and existing customers.

We had goodwill of $27.7 million at December 31, 2023, none of which is currently believed to be at risk for future impairment.

We remain committed to providing employees and their families with simple, modern, and personal benefit solutions. During 2024, we will continue to utilize our strong distribution system of independent agents, benefit counselors and broker partnerships. We will also continue to invest in solutions and digital capabilities to expand our reach and effectiveness, driving growth and improving productivity while enhancing the customer experience. In 2024, we will continue to bring an enhanced engagement and enrollment platform to market, enabling deeper connections with employees through the enrollment process as well as maintaining stronger relationships throughout the customer lifecycle. We believe our distribution system, customer service capabilities, digital and virtual tools, and ability to serve all market sizes position us well for future growth.

In 2024, we expect strong growth in adjusted operating income for the full year with sales and premium growth increasing from the prior year. We expect improved claim experience in 2024 but could continue to experience some level of claims volatility. While we believe our underlying profitability will remain strong, current economic conditions and increasing competition in the voluntary workplace market are risks to achievement of our business plans. We continuously monitor key indicators to assess our risks and adjust our business plans accordingly.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.